Hemolytic Uremic Syndrome

Adults and children with atypical hemolytic uremic syndrome who switched from eculizumab to ravulizumab had stable renal function and hematologic values with similar safety seen in clinical trials, according to data from a registry study.

Ravulizumab was successful in improving blood health, kidney function and quality of life while maintaining eGFR in pediatric and adult patients with atypical hemolytic uremic syndrome, according to published data.